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ABSTRACT
IRF1 is a transcription factor that regulates key pro-
cesses in the immune system and in tumour sup-
pression. To gain further insight into IRF1’s role in
these processes, we searched for new target genes
by performing chromatin immunoprecipitation
coupled to a CpG island microarray (ChIP–chip).
Using this approach we identified 202 new
IRF1-binding sites with high confidence. Functional
categorization of the target genes revealed a sur-
prising cadre of new roles that can be linked to
IRF1. One of the major functional categories was
the DNA damage response pathway. In order to fur-
ther validate our findings, we show that IRF1 can
regulate the mRNA expression of a number of the
DNA damage response genes in our list. In particu-
lar, we demonstrate that the mRNA and protein
levels of the DNA repair protein BRIP1 [Fanconi
anemia gene J (FANC J)] are upregulated after
IRF1 over-expression. We also demonstrate that
knockdown of IRF1 by siRNA results in loss of
BRIP1 expression, abrogation of BRIP1 foci after
DNA interstrand crosslink (ICL) damage and hyper-
sensitivity to the DNA crosslinking agent, melpha-
lan; a characteristic phenotype of FANC J cells.
Taken together, our data provides a more complete
understanding of the regulatory networks controlled
by IRF1 and reveals a novel role for IRF1 in regulat-
ing the ICL DNA damage response.
INTRODUCTION
The interferon regulatory factor (IRF) family of proteins
are important for the proper functioning and homeostasis
of mammalian systems (1). The diﬀerent family members
play important roles in development, diﬀerentiation
and immunity. In particular, IRF1 has been shown to be
involved in immune responses and regulation of T-cells
and myeloid cells in the immune system, cell cycle,
tumour suppression and apoptosis (2–4). Most of IRF1’s
activity results from its binding to genes involved in these
pathways and regulation of their expression. DNA-
binding studies demonstrated that IRF family members
bind to a consensus sequence, termed IRF-E which
is very similar to the ISRE (interferon stimulated response
element) found in many interferon regulated genes (5).
IRF1 is induced in response to a number of stimuli
including, IFN-g, retinoids, TNFa, bacterial infection
and anti-estrogens. Gene knock out studies in mice iden-
tiﬁed IRF1 as an important immune cell regulator.
IRF1
–/– mice have aberrant lymphocyte development
and when challenged with speciﬁc bacteria mount a type
2T-helper cell response, with a marked absence of IFN-g-
producing type 1T cells (6,7). This is thought to occur
due to the absence of IL-12 and IL-18 in IRF1 null
mice. IRF1 has also been shown to control positive and
negative selection of CD8
+ thymocytes (8). The authors
showed that there was an intrinsic defect in IRF1
–/– thy-
mocytes suggesting that IRF1 is required for lineage com-
mitment and selection of CD8
+ thymocytes. IRF1 is also
essential for natural killer (NK) cell function in vivo and in
the microenvironment supporting NK cell development
(9,10). IRF1 can aﬀect tumour susceptibility in mice and
harbours tumour suppressor activity (11). Diﬀerent can-
cerous lesions undergo loss of IRF1 expression by chro-
mosome deletion, exon-skipping and functionally
inactivating point mutation (12,13). It has also been
demonstrated that both IRF1 and p53 are required to
prevent oncogene-induced cell transformation (14) and
IRF1 can reverse the transformed phenotype both
in vitro and in vivo (15).
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immune system and in cancer will be the identiﬁca-
tion of direct target genes. To date, there are still rela-
tively few gene targets mapped for IRF1. The
binding of a transcription factor to the regulatory region
of a speciﬁc gene suggests that the factor will have
some regulatory eﬀect on that gene. Therefore, to gain a
deeper insight into IRF1-mediated regulatory networks
we have undertaken a ChIP–chip study to locate
IRF1-binding sites in the human genome. Using this
approach, we have identiﬁed 202 new loci bound by
IRF1 after IFN stimulation. We validated several of
these targets by ChIP in two diﬀerent cell lines and by
RT–PCR of IFN-g treated or IRF1 over-expressing
cells. We observed a high ChIP validation rate (>90%)
and diﬀerential transcript regulation by IFN or IRF1.
Importantly, novel functions for IRF1 have emerged
from this study and newly identiﬁed IRF1 bound genes
can help to explain the phenotypes observed in IRF1
knockout mice.
Interestingly, a large cohort of the target genes fell
under the DNA damage response category (9%).
Although, a number of studies have demonstrated a
strong link between IRF1 and DNA damage repair, very
little is known about the target genes regulated by IRF1 in
this response. We have demonstrated that one of the
target genes; BRIP1 (a Fanconi anemia gene J, FANC
J) is upregulated in response to IFN and IRF1 over-
expression at the mRNA and protein level. We
have demonstrated at the single cell level using immuno-
ﬂuorescence studies that downregulation of IRF1 by
siRNA results in loss of BRIP1 expression and abroga-
tion of BRIP1 foci after DNA crosslink damage.
Furthermore, we demonstrate that cells that have had
IRF1 expression knocked-down by small interfering
RNA show a hallmark hypersensitivity to the DNA cross-
linking agent, melphalan [similar to the phenotype dis-
played by Fanconi anemia (FA) cells]. Signiﬁcantly,
these results reveal a previously unknown role for
IRF1 in regulating the DNA interstrand crosslink (ICL)
repair pathway.
MATERIALS AND METHODS
Cells,transfection andantibodies
H3396 breast cancer cells were grown in RPMI (Lonza)
and the MRC-5 lung ﬁbroblasts were grown in MEM-
alpha (Lonza). IFN-g and Melphalan were purchased
from Sigma. Antibodies used for ChIP–chip, western
blots and ChIP are rabbit polyclonal anti-human IRF1
(C-20), normal rabbit IgG (sc-2027) and anti-tubulin
(Santa Cruz Biotechnology), anti-BRIP1 (Autogen
Bioclear). H3396 cells were plated on a 10cm plate the
day before transfection. Cells were re-fed prior to trans-
fection (Lipofectamine, Stratagene) with 3mg each of
pCDNA-IRF1 or pCDNA 3.1 empty vector control.
Twenty-four hours after transfection, the cells were lysed
as per the manufacturer’s protocol (Invitrogen) and RNA
extracted for RT-PCR analysis.
RNA extraction and RT-PCR
RNA was extracted from H3396 cells using the RNA-
EASy kit (Qiagen). For cDNA synthesis, 3mg of total
RNA was reverse transcribed using the Superscript II kit
(Invitrogen). Then 1/100th of each sample was used in
semi-quantitative PCR using gene-speciﬁc primers. Real
time PCR was performed on the MX3005 real-time PCR
(Stratagene). Primer sequences are available upon request.
ChIP
ChIP experiments were carried out as described in (43),
with the exception that the Real-time PCR machine used
was the MX3005P (Stratagene). The locations of the
primer pairs used in the PCR reaction are depicted in
Supplementary Figure 2. Primer sequences are available
upon request.
Generation ofChIP amplicons forChIP–chip
DNA amplicons for ChIP–chip were generated from three
independent ChIP samples (IRF1 or IgG). Brieﬂy, ChIP
samples from each experiment (done in duplicate) were
pooled and amplicons generated by LM-PCR following
the protocol described (16). Brieﬂy, three rounds of ampli-
ﬁcation were performed on T4 blunted ChIP samples to
which two unidirectional linkers were annealed. Reactions
were puriﬁed using the Qiagen PCR cleanup kit (Qiagen).
After puriﬁcation, the DNA amplicons were quantiﬁed
and examined on a 2% agarose gel for size. Gene-speciﬁc
PCRs were then carried out to ensure that the initial
enrichment of control test genes was maintained. The
average size of the amplicons was approximately 300bp
(ranging from 200 to 500bp). Input DNA was also sub-
jected to LM-PCR and input amplicons were then used as
a reference for hybridization to a 12K CpG island (CGI)
array.
Labelling, hybridization and analysis of the12K CPG array
The 12K Human CPG microarray was purchased from
the University Health Network (Toronto, Canada).
DNA amplicon samples were labelled according to the
protocol as described in (16). The hybridized arrays were
scanned using a ScanArray 4000 (Perkin-Elmer, USA)
and analysed using the Imagene 5.0 analysis software
(BioDiscovery, Inc., USA). Spots that did not meet the
quality control parameters after visual inspection or by
the analysis software were discarded. Raw median values
were normalized using the software ChiPper. Data is
returned ranked according to increasing p-value. For
each CpG clone, the ranked P-value is from two datasets
for each antibody (anti-IRF1 or normal rabbit IgG).
Target loci were then identiﬁed by a P-value cut-oﬀ of
0.001. Visualization and manual assignment of ‘target’
genes within 100kb of regions corresponding to the CpG
clone was performed using the UHN CpG microarray
database (http://data.microarrays.ca/cpg/). Functional
classiﬁcation of genes was carried out using the DAVID
Functional annotation tool (http://david.abcc.ncifcrf.
gov/). The background list used in the analysis was
1074 Nucleic Acids Research, 2009, Vol. 37,No. 4generated from all the non-redundant genes within 100kb
of clones on the CGI array.
Flow cytometry
Cells were treated for 1h with vehicle or 1mM Melphalan
16h after transfection with 25nM IRF1 siRNA or control
siRNA (Dharmacon-On Target Smartpool). Cells were
then washed and re-fed with medium containing 10%
Fetal Calf Serum and left to recover for 48h. Cells were
collected, washed 2  in PBS and ﬁxed in 70% ethanol
solution overnight. The next day cells were collected,
washed in PBS and treated with RNAse A for 30min at
room temperature and then stained with propidium iodide
(50mg/ml). Cell cycle analysis was performed on a Becton
Dickinson FACSARIA SORP using the DIVA software.
Further analysis was performed using the program
WINMDI.
Immunoflourescence
We carried out immunoﬂuorescence microscopy studies
on cells grown on coverslips. Cells were ﬁxed and permea-
bilized as described (16). Coverslips were then washed in
PBS and incubated in 1% PBS/BSA for 30min.
Afterwards, the coverslips were washed again in PBS
and incubated overnight (48C) in primary antibody,
anti-human BRIP1 (1:300) (Santa Cruz Biotechnology).
The next day, coverslips were washed in PBS and left
for one hour in anti-mouse Alexa Fluor 488 conjugated
secondary antibody (1:1000). Then coverslips were
washed again in PBS and left for two hours with anti-
human IRF1 antibody (1:1000) (Abcam). Coverslips
were washed in PBS and then placed in anti-rabbit
Alexa Fluor 543 conjugated secondary antibody
(1:1000). All secondary antibodies were purchased from
Molecular Probes, Invitrogen. A ﬁnal wash in PBS was
carried out and then coverslips were mounted on a glass
slide in anti-fade solution (Vector Laboratories Ltd.).
Images were acquired on a Zeiss LSM510 Meta laser scan-
ning microscope.
RESULTS
Identification ofloci bound by IRF1
To identify novel target genes of IRF1, we performed
ChIP–chip experiments on breast cancer cells (H3396).
First, we examined the expression of IRF1 after IFN-g
treatment of cells. We observed the expected increase in
IRF1 after stimulation with maximal expression of IRF1
after 3h IFN-g treatment (Figure 1A). This time point was
then chosen to perform the genome wide ChIP studies on
the 12K CGI array. Cross-linked chromatin was immuno-
precipitated with a polyclonal antibody against IRF1 and
a normal rabbit (control) IgG antibody was used as a
negative control. Figure 1B shows the enrichment of
IRF1at two known targets (TRAIL and caspase 8).
The 12K array contains genomic fragments from
human CGI (17). We chose this array since (i) CGIs are
known to be located in regulatory regions of genes (18,19)
and there is a strong correlation between CGIs and
clusters of transcription-factor-binding sites (20), (ii) it
allowed us to screen a large number of loci in the
human genome for IRF1 binding. We performed three
hybridizations using independent ChIP generated ampli-
cons. The raw ChIP–chip ﬂuorescence intensity data were
processed using ChIPper (21), a data analysis system that
normalizes and scores microarray data generating
P-values for each clone. We next eliminated redundant
clones and those not mapping to known locations in the
human genome. As a further control, we also generated a
list of ranked clones from the IgG amplicon hybridiza-
tions. There was a very limited overlap in the two lists
after the cut-oﬀ and the few IgG enriched clones that
had similar p-values were removed from the IRF1 list of
positive clones. Using a stringent cut-oﬀ P-value <0.001
and based on their location within 100kb of transcription
units (according to the hg18 NCBI build), we assigned the
remaining clones to 202 genomic loci. The list of the genes,
with the chromosomal position (of the CGI clone), as well
as P-values, can be found in Supplementary Data 1.
Validation oftargets
We next sought to verify that the genomic loci we identi-
ﬁed by ChIP–chip are indeed bound by IRF1. H3396 cells
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Figure 1. Western blot of IRF1 expression and control ChIP. (A)
H3396 cells were left untreated (control) or treated with IFN-g for
the time points indicated. Shown is a western blot analysis of whole
cell extracts made at each time point using an antibody against IRF1 or
actin as loading control (B) Shown is quantitative real-time PCR of a
ChIP sample from formaldehyde-ﬁxed H3396 cells used for ChIP–chip.
Cells were untreated (control) or treated with IFN-g for 3h and immu-
noprecipitated with control IgG or anti-IRF1 antibody. Two positive
control genes are shown, caspase 8 and TRAIL.
Nucleic Acids Research,2009, Vol.37, No. 4 1075were left untreated or treated with IFN-g for 3h and DNA
prepared from three independent ChIP experiments.
Quantitative PCR was performed on 21 loci from our
list of IRF-enriched genes. These loci were chosen from
across the range of P-values in order to determine the
stringency of our cut-oﬀ. To design primer pairs, we exam-
ined 1kb upstream or downstream of the CGI clone for
IRFEs or IRF-binding elements. The consensus binding
sites for IRFs are well established referred to as IRFEs or
ISREs (5). Almost all regions in the vicinity of the clones
contained consensus IRFEs (Supplementary Data 1). We
selected primers ﬂanking potential IRF1-binding sites due
to the suitability for generating single PCR fragments
from the human genome. We also selected a pair of pri-
mers from the UNG gene as controls. Supplementary
Figure 2 shows a schematic of the loci chosen for valida-
tion with the position of the CGI clone, consensus IRFEs
(for a list of the IRFEs identiﬁed at each loci, see
Supplementary Figure 6) and the primer pairs used for
qPCR.
Figure 2 shows the results of the validation. Seven loci
were strongly enriched for IRF1 binding after IFN treat-
ment. These were OAS3, CCNT2, NFATC2IP, ACP2,
PSMA6, C14orf43 and C6orf170. Most of these genes
with the exception of NFATC2IP (P-value=0.00041)
ranked at the top of our enriched list according to
P-value. Signiﬁcantly, the top ranked gene, OAS3 has
been shown previously to contain consensus IRFE/
ISREs in its regulatory regions. This suggested that it
was a target for IFN regulatory factors (22) which has
now been conﬁrmed by our study. The remaining 14
genes validated were also signiﬁcantly enriched for IRF1
after IFN-g treatment. The level of IRF1 enrichment in
this group of genes also correlated well with their position
in our ranked list according to p-value. It is notable that
major histocompatability genes (23), as well as histone
genes, (24) are regulated by IRFs. Primers to the UNG
gene that were used as a negative control gave no enrich-
ment for IRF1 over the background IgG ChIP (Figure 2).
Two loci (C3orf26 and YWHAB) chosen from our target
list for qPCR did not show signiﬁcant enrichment for
IRF1 in H3396 cells (data not shown). We also observed
that a known gene target of IRF1, c-myc (1) was identiﬁed
in our cohort of genes as relatively enriched for IRF1
binding (P-value=0.0013) but fell below our cutoﬀ
P-value. This further validates our ﬁndings and suggests
that other true IRF1 target genes might fall below our
threshold, indicating that our cutoﬀ value has been strin-
gent. Overall, we obtained a validation rate of >90%
(19/21), indicating that the list comprises a large number
of bona ﬁde IRF1-bound genes.
Binding ofIRF1 in primary human lung fibroblast cells
We next wanted to determine if the loci tested for IRF1
binding in breast cancer cells would be bound by IRF1
after IFN treatment in another cell line. We chose the
MRC5 primary lung ﬁbroblast cell line, as this represented
a normal diploid cellular environment. We ﬁrst deter-
mined that IRF1 was induced in these cells after IFN-g
induction (Supplementary Figure 3A). Again, we observed
an up-regulation of IRF1 protein levels after IFN induc-
tion that was maintained up to 24h. For consistency, we
chose to use the 3h time point to perform the ChIPs. As
shown in Supplementary Figure 4, all the genes tested
showed similar enrichments (slightly higher in a few
cases) for IRF1 after IFN treatment. Again, the UNG
primers showed no enrichment for IRF1 after IFN treat-
ment. Overall, IRF1 is bound to the same genes after
IFN stimulation in both cell types and this indicates that
these genes are bona ﬁde targets of IRF1 after IFN
stimulation.
We also assayed the binding of IRF1 to the ChIP–chip
enriched genes in the absence of IFN (untreated cells). In
both cell types (Figure 1 and Supplementary Figure 3A)
we observed that IRF1 is constitutively expressed at a low
level in the absence of IFN. Half of the genes displayed
enrichment for IRF1 in control (non-IFN stimulated) cells
compared to the background enrichment with the control
IgG antibody (Figure 2 dark grey columns and
Supplementary Figure 4 light blue columns). This indi-
cates that IRF1 is bound to some of its targets prior to
IFN stimulation of cells and it may play a role in their
regulation in cycling cells.
Functional categories of target genes
An important aspect of this high-throughput approach is
that we can assign new role(s) for IRF1 in diﬀerent bio-
logical processes by looking for statistically signiﬁcant
functional categories in our list of genes. In order to do
this, we functionally classiﬁed the ChIP–chip enriched
genes into Gene Ontology (GO) categories. We performed
this analysis using the DAVID functional annotation tool.
Functional categorization revealed a diverse set of GO
biological processes that were statistically signiﬁcant in
our list of genes compared to the background list,
P-value < 0.10. Enriched categories included DNA meta-
bolism, antigen processing, protein transport, response to
DNA damage and transcription. Strikingly, we found that
8 out of the 92 genes ( 9%) on the CGI array mapping to
the GO DNA damage category were bound by IRF1 in
our study (Figure 3 and Supplementary Figure 5). It is
known that IRF1 is involved in the response of cells to
DNA damage such as g-irradiation (25,26) and may play a
role in DNA repair processes (27). However, the full
nature of its involvement and/or which IRF1 target
genes might be involved in this process was not known.
Moreover, it is known that IRF1 expression is stabilized in
cells treated with DNA damaging agents (28) resulting in
elevated levels of IRF1 similar to induction by IFN.
Taken together the data support the idea that IRF1
plays a signiﬁcant role in DNA damage/repair pathways
via direct transcriptional regulation of genes involved in
these processes.
As a number of the genes were not assigned to GO
categories by DAVID, we sought to further categorize
the genes by combining GENE Ontology data with liter-
ature supporting speciﬁc roles for the genes in the NCBI
database. We manually assigned genes into GO biological
processes revealing a number of novel functions. These
included translation, chromosome organization and
1076 Nucleic Acids Research, 2009, Vol. 37,No. 4biogenesis, signal transduction and cell adhesion. Figure 3
is a summary of this functional categorization. We identi-
ﬁed a large number of genes involved in the immune/
inﬂammatory or defence response. Importantly, these
novel immune regulatory genes have not previously been
linked to IRF1 and may be very important in under-
standing why IRF1 knockout mice display immune
dysfunction (29).
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Figure 2. ChIP validation of targets. H3396 cells were untreated (dark grey bars) or treated with IFN-g for 3h (light grey bars) to induce IRF1
expression. ChIP was performed with control IgG or anti-IRF1 antibody. Shown is real-time PCR of immunoprecipitated DNA for IRF1 gene
targets identiﬁed on the CGI array. Data are from three independent ChIP experiments  SD. The data is displayed as Percent of INPUT chromatin.
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IRF1 is a direct IFN response gene and is upregulated by
both type I and type II IFNs, where IFN-g is a strong
inducer of its expression (Figure 1A). As a positive con-
trol, we have determined the mRNA level of IRF1 after
IFN stimulation (5h and 24h time points) using semi-
quantitive RT-PCR (Figure 4A). As expected, we
observed a large induction of IRF1 mRNA, 40–45-fold
after IFN stimulation. Next, we determined the relative
steady state mRNA levels of selected loci from our list
of IRF1 enriched genes. In most cases, we selected the
same genes as those used in Figure 2 in order to correlate
expression to binding/recruitment. A number of tran-
scripts showed transient up-regulation after IFN stimula-
tion. These are LIG4, C6orf170 and PCNA. Other
transcripts were up-regulated and remained up such as,
BRIP1 (FANC J) CTDSPL2, NSMCE2 and PSMA6.
Interestingly, the level of some of the transcripts did not
change signiﬁcantly at the time points tested after IFN
stimulation. This phenomenon, where a transcription
factor is recruited or bound at speciﬁc genes without any
apparent consequences on the level of transcription, has
been increasingly observed in diﬀerent ChIP–chip studies
(30–32). IRF1 can also repress transcription at a number
of genes such CDK2 and CYCLIN D1, although we did
not observe this eﬀect on the set of genes we tested so far.
Thus, IRF1 recruitment/binding seems to have variable
eﬀects on the level of transcription at a speciﬁc locus but
it cannot be ruled out that other transcription factors also
need to be recruited at a gene for a speciﬁc response to
IFN. It may also be that other signals must be integrated
in order to produce a change in the level of transcription.
In order to have a more direct determination of IRF1’s
eﬀect on a speciﬁc locus, we over-expressed IRF1 by tran-
sient transfection (Figure 4B) and determined the level of
endogenous transcripts by semi-quantitative PCR. We
observed signiﬁcant changes in the transcript level of six
IRF1-bound genes after over-expression of IRF1 in
H3396 cells, which correlated with the changes we
observed after IFN treatment. Among the genes tested
were four genes from the DNA damage functional cate-
gory, BRIP1, PCNA, LIG4 and NSMCE2. These results
suggest that IRF1 is a major player in the regulation of
these genes by IFN-g or other signals resulting in IRF1
recruitment to these genes. As a control, the level of
expression of the TRAIL mRNA (a known target of
IRF1) was determined. As expected there was a large
increase in the level of TRAIL transcript after expression
of the IRF1 cDNA.
IRF1 over-expression orIFN-ccan upregulate expression
of BRIP1
One of the major functional categories identiﬁed in our
ChIP–chip study was DNA damage and repair. Among
these genes is BRIP1 that has a high ranking in our list of
genes, P-value 0.000076. We found that expression of this
gene is signiﬁcantly upregulated at the mRNA level after
both, IFN treatment and IRF1 overexpression in breast
cancer cells (Figure 4A and B). These results coupled to
the fact that this gene could be an unknown link between
IRF1 and DNA damage, led us to investigate the regula-
tion of BRIP1 by IRF1 in more detail. We wanted to
determine if overexpression of IRF1 in cells would lead
to an upregulation of BRIP1 protein similiar to what we
observed at the mRNA level. Indeed, transfection of
MRC5 ﬁbroblast cells with increasing amounts of
pCDN3A-IRF1 resulted in a concomitant increase in
BRIP1 protein levels (Supplementary Figure 3B).
IRF1 knockdown abrogatesICL damage inducible
BRIP1 foci
The protein BRIP1 is a member of the FA family of pro-
teins, known as FANC J (33). These proteins are involved
in the repair of ICLs in DNA and BRIP1 is known to
form foci at DNA damage sites in response to ICL
reagents (34). We reasoned that if IRF1 were involved in
regulating BRIP1 expression in cells, which depletion of
IRF1 by small interfering RNA (siRNA) would result in
deregulation of BRIP1 expression or foci formation.
Therefore, we performed immunoﬂuorescence experi-
ments and confocal microscopy to look at individual
cells and the response to melphalan after IRF1 knock-
down. We determined the levels of BRIP1 and IRF1at
the single cell level, before and after ICL damage. In
cells transfected with control siRNA, we observed a
clear nuclear staining for IRF1 (Figure 5A and B),
which is consistent with other studies showing IRF1 as a
mainly nuclear protein (35). In control cells, BRIP1 also
displayed nuclear staining (Figure 5A). We observed no
co-localization of these two proteins (see merged,
Figure 5). After control cells were treated with melphalan
(Figure 5B), we observed a large increase in BRIP1 foci. In
contrast, cells transfected with IRF1 siRNA, displayed
very weak residual BRIP1 staining (Figure 5C) and no
staining for IRF1. After melphalan treatment of IRF1
GO Term Name CpG Island Array Experimental Set
(IRF1 Positive)
Percent of IRF1
positive clones
mapped to a
Go Term from the
CpG array
P-value (<0.10)
DNA  metabolism 143 15 10.5% 3.00e-2
Transcription 912 38 9.00e-2
Antigen processing 14 3 21.4% 5.70e-2
213 13 6.1% 6.90e-2
Response to DNA
damage stimulis
92 8 3.10e-2
Protein transport
4.2%
8.7%
Figure 3. GO functional enrichment. The table shows the statistical
enrichment of GO categories assigned to the target gene list with
P-value <0.10. Enrichment was calculated using the non-redundant
list of genes on the CGI array as the background set (from the
UHN CGI Microarray database) and the IRF1 target gene list (see
Supplementary Figure 3). Statistical analysis was performed using the
DAVID software. From right to left; column 1—GO term name from
DAVID; column 2—number of genes on the CGI array mapping to the
GO term; column 3—number of IRF1 bound genes mapping to the GO
term; column 4—percentage of GO-mapped genes bound by IRF1
(column 3/column 2); column 5—statistical signiﬁcance (P-value).
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Nucleic Acids Research,2009, Vol.37, No. 4 1079knockdown cells, we observed no DNA damage induced
BRIP1 foci (compare BRIP1 in Figure 5D to B). These
results demonstrate that IRF1 is involved in regulating the
expression of the BRIP1 protein in undamaged cells and
that BRIP1 foci formation after ICL (melphalan) damage
is dependent on IRF1 expression. The fact that we
observed a very low level residual BRIP1 staining in
untreated cells (that did not change after melphalan treat-
ment), argues that there are other factors that may also be
responsible for regulating expression of BRIP1 in unda-
maged, cycling cells such as E2F1, which has recently been
shown to regulate its expression (36).
A
B
BRIP1 IRF1 Merged DAPI
C
D
Figure 5. IRF1 expression is required for BRIP1 expression and foci formation after ICL damage. MRC5 cells transfected with 50nM of control
(A, B) or IRF1 siRNA (C, D) were treated with 500nM melphalan (B, D) for 16hrs and stained with either IRF1 or BRIP1 antibody as indicated
and with DAPI.
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Our immunoﬂuorescence data then prompted us to probe
whether IRF1’s regulation of BRIP1 could link IRF1 to
the ICL repair pathway. Therefore, we next determined if
downregulation of IRF1 could aﬀect the sensitivity of cells
to ICL inducing agents. It is known that treatment of FA
cells with DNA crosslink reagents such as mitomycin C or
melphalan results in a marked hypersensitivity with
increased accumulation of cells in G2/M or with near
4N DNA content (37,38). In order to test this, we
decreased IRF1 protein levels using IRF1 siRNA
(Figure 6A) and determined the DNA content of cells
by cell cycle analysis using propidium iodide. This exper-
iment was performed in cells before and after treatment
with melphalan. Interestingly, we observed an increased
hypersensitivity to melphalan in cells with decreased
levels of IRF1 protein. Cells with IRF1 siRNA had a
marked increase in 4N DNA content compared to cells
transfected with the control siRNA (Figure 6B and C).
These results demonstrate that a deﬁciency in IRF1
leads to a defect in ICL repair and hypersensitivity to
crosslinking agents.
DISCUSSION
IRF1 is a transcription factor controlling anti-cancer,
apoptotic and immune/inﬂammatory responses. To
understand the role of IRF1 in these responses, the
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Figure 6. Knockdown of IRF1 results in hypersensitivity to melphalan with increased accumulation of cells in G2/M. (A) MRC5 cells were
transfected with 25nM of control siRNA or IRF1 siRNA and treated with vehicle or melphalan (1mM) for 1h. Western blot analysis shows
IRF1 protein levels in control and IRF1 siRNA transfected cells after 64h. b-actin is shown as a control. (B) Cell cycle analysis was performed on
the above cells. Shown is a graph depicting the percent of cells with 4N (G2/M) DNA content as measured by propidium iodide uptake, Student
t-test and
 P-value is 0.007. Data shown are the mean of three experiments  SD. (C) A representative experiment is shown from the ﬂow cytometric
analysis of cells transfected with control or IRF1 siRNA for 16h and then treated with melphalan (1mM) for 1h. Cells were collected and stained
with propidium iodide 64h after transfection.
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Therefore, we performed a ChIP–chip analysis to identify
IRF1-binding sites in the human genome. Using this
approach, we were able to identify 202 novel loci that
are enriched for IRF1 binding after IFN treatment of
cells. The validation experiments conﬁrmed that >90%
of these loci are bound by IRF1 in vivo, proving the eﬀec-
tiveness of our approach. Correlation of ChIP-validated
genes with expression analysis, after IFN treatment or
over-expression of IRF1, showed that at least half of the
bound genes were regulated after IRF1 recruitment/bind-
ing. We also identiﬁed consensus IRFEs or ISREs in the
close vicinity of most of the CGI clones. These results
increase our conﬁdence in the ranking and identiﬁcation
of IRF1 bound genes.
Functional characterization of the bound genes revealed
that IRF1 potentially controls many diverse processes in
mammalian systems. Importantly, most of the bound
genes identiﬁed have not been previously linked to
IRF1. Our results suggest that IRF1 is involved in regu-
lating genes that encode components of the DNA damage
response and DNA repair pathways, as well as factors
involved in chromatin biogenesis and organization, cell
cycle processes, transport (protein and vesicle-mediated),
immune and inﬂammatory responses, and transcription.
IRF1 tumoursuppressor activity may be linked tonew
targetsidentified by ChIP–chip
We have identiﬁed new IRF1 bound genes that may play a
critical role in its tumour suppressor activity (11). Some of
IRF1’s tumour suppressor activity is linked to its immune
regulatory functions (39–41) but it also has cell intrinsic
anti-cancer activity that has not been fully characterized.
IRF1 is involved in a range of processes aﬀecting cancer
formation such as DNA damage responses, cell cycle and
apoptosis but very few genes in these categories have actu-
ally been deﬁned as IRF1 target genes. IRF1 is well
known to induce two apoptotic factors, TRAIL and cas-
pase 8 (42,43) and the cell cycle inhibitor p21 is induced by
IRF1 in cooperation with the tumour suppressor p53 (25).
Recently, the tumour suppressor activity of IRF1 has also
been linked to the downregulation of cyclin D1 (44) and
survivin (45).
Supplementary Figure 7 lists the IRF1 bound genes that
have been shown to harbour anti-proliferative or tumour
suppressor activity. Two of these genes, BRIP1 and
BARD1, are important proteins that interact with the
breast cancer tumour suppressor gene, BRCA1 (46,47).
IRF1 is able to inhibit the growth of mammary tumour
cells in vitro and in vivo, in mouse tumour xenograft
models (48) and is involved in the repression of mammary
tumour cells after treatment with tamoxifen (49). Also,
IRF1 expression negatively correlates with breast
tumour grade, where high-grade tumours were less likely
to maintain expression of IRF1 (50), suggesting that IRF1
expression may be antagonistic to breast cancer progres-
sion. The fact that two genes important in the mainte-
nance of genomic integrity in mammary cells have been
found in our list of target genes reinforces this idea. Five
other target genes, HPGD, PLAGL1, RASSF5, AKAP12
and DCC have been reported to harbour tumour suppres-
sor activity. (51–61). It will be of interest in future studies
to identify the role of these individual genes in IRF1’s
anti-cancer activity.
New functionalrole forIRF1 in regulating DNA interstrand
crosslink repair
In addition to the above genes, novel IRF1 bound genes
identiﬁed included a large subset of genes involved in
DNA damage responses and DNA repair. Here, we have
provided evidence that IRF1 plays a previously unknown
role in regulating ICL repair. We have shown that IFN-g
that highly induces IRF1 expression results in increased
IRF1 binding at the promoter region of the BRIP1 gene.
This binding results in gene activation since over-expres-
sion of IRF1 leads to upregulation of BRIP1 mRNA and
protein. BRIP1 was initially identiﬁed as an interacting
partner of BRCA1 (62) and is a member of the FA protein
family (63). FA is a multigene disease, characterized by
bone marrow failure and developmental abnormalities.
These proteins have been shown to play essential roles
in DNA repair and owing to this, FA cells have a high
degree of genomic instability and cancer predisposition
(33,64–67). In particular, the FA pathway has been
shown to play an important role in DNA ICL repair,
where FA cells display a hallmark ‘hypersensitivity’ to
DNA cross-linking agents. There are 13 family members
to date; with BRIP1 being the FA protein J that forms
part of the Group III FA proteins which function down-
stream of the Group II FA proteins (FANCD2 and
FANCI) in DNA repair (for a more comprehensive dis-
cussion, please see Wang, 2007 and references within). The
exact role that BRIP1 plays has not been fully elucidated
but it has been hypothesized to facilitate homologous
recombination or translesional bypass at stalled replica-
tion forks (33,63).
Given BRIP1’s important role in the FA pathway, we
wanted to test if IRF1 might then be involved in regulat-
ing DNA damage responses to ICLs. Indeed, our data
supports an active role for IRF1 in regulating this repair
pathway, as cells with diminished IRF1 expression are
hypersensitive to the DNA cross-linking agent, melphalan.
It is important to note that this hypersensitivity is a pecu-
liarity of FA null cells or cells with defects in other pro-
teins that have been shown to aﬀect the ICL repair
pathway (68,69). Thus, these data deﬁnitively link IRF1
to repair processes required for resolution of ICLs.
Importantly, we could not detect appreciable BRIP1
expression in IRF1 knockdown cells. We also show that
in the absence of IRF1 expression there is an abrogation
of BRIP1 foci in ICL damaged cells. We conclude from
these results that IRF1 is important for maintaining levels
of BRIP1 in cells and subsequently for the formation of
suﬃcient BRIP1 foci after ICL damage. The known fact
that loss of BRIP1 expression in cells results in hypersen-
sitivity to cross-linking agents (63,70) suggests that the
major defect contributing to the ICL hypersensitivity we
observe in IRF1 knockdown cells is the abrogation of
BRIP1 expression. Although, we cannot rule out that
other DNA repair or DNA damage response genes
1082 Nucleic Acids Research, 2009, Vol. 37,No. 4regulated by IRF1 are also involved in the ICL hypersen-
sitivity of IRF1 knockdown cells. Our ChIP–chip study
has identiﬁed a number of other target proteins involved
in DNA repair such as PCNA. It will be of interest in the
future to determine the extent to which IRF1 regulates
these other DNA repair proteins and whether they are
also involved in DNA damage responses where IRF1 is
involved.
In summary, we have successfully identiﬁed several
bona ﬁde IRF1 bound genes, before and after IFN stim-
ulation in two cell types. Since IRF1 was ﬁrst identiﬁed,
many studies have elucidated its’ role in the immune
system and in tumour suppression. We have been success-
ful in greatly strengthening these known roles by identify-
ing many novel gene targets of IRF1 that are involved
in these two processes. We have also been able to dem-
onstrate a new function for IRF1, the regulation of
DNA ICL repair. IRF1 regulates one of the components
of the FA/BRCA DNA repair pathway, BRIP1. This
pathway is important for maintaining genomic integrity
in cells after genotoxic insult. Moreover, BRIP1 is a
newly identiﬁed breast cancer susceptibility gene, with a
doubling of breast cancer risk (71–73). Therefore, our data
linking IRF1 to BRIP1 further demonstrates and better
explains IRF1’s role as a known tumour susceptibility
gene (11).
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